Alios BioPharma
260 East Grand Avenue
2nd Floor
South San Francisco
California
94080
United States
Tel: 650-635-5500
Fax: 650-872-0584
Website: http://www.aliosbiopharma.com/
24 articles about Alios BioPharma
-
In a filing with the U.S. Securities and Exchange Commission, Johnson & Johnson said it will abandon development of AL-8176, one of the assets it acquired in the Alios deal.
-
Alios BioPharma Release: New Data Published In The New England Journal of Medicine Shows Potential Of Compound To Fight RSV Infection In Adults And Children
11/19/2015
-
Johnson & Johnson Announces Completion Of Alios BioPharma Acquisition
11/10/2014
-
Alios BioPharma To Present Preclinical Data On Its Anti-HCV Nucleotides AL-335 And AL-516 At The 2014 American Association for Study of Liver Diseases Annual Meeting
11/7/2014
-
Alios BioPharma Presented Positive Results Of Its Anti-RSV Nucleoside Analog AL-8176 In A Phase 2 Challenge Study In Adults Infected With Respiratory Syncytial Virus (RSV) At IDWeek
10/13/2014
-
Alios BioPharma’s Corporate Venture Backers Ride RSV (And Hep C) To A Big Payday
10/2/2014
-
Johnson & Johnson Bags SSF's Alios BioPharma For $1.7 Billion Cash
10/1/2014
-
Alios BioPharma Presents Data On Its Anti-HCV Nucleotide AL-335 At Special Conference On Hepatitis C
9/15/2014
-
Alios BioPharma Announces Upcoming RSV & HCV Scientific Presentations
9/15/2014
-
Retroscreen Conducts Landmark hVIVO Human Challenge Model Study Of AL-8176 In RSV For Alios BioPharma
7/28/2014
-
Alios BioPharma Reports Positive Results Of Its Anti-RSV Nucleoside Analog AL-8176 In A Phase 2 Challenge Study In Adults Infected With Respiratory Syncytial Virus (RSV)
7/24/2014
-
South San Francisco's Alios BioPharma Raises $41 Million In Series B Financing
4/7/2014
-
Alios BioPharma Reports Significant Progress With Its Clinical Program For AL-8176, Its Nucleoside Analog For The Treatment Of Respiratory Syncytial Virus (RSV)
1/13/2014
-
Alios BioPharma Presented Data on Its First-in-Class Anti-Respiratory Syncytial Virus (RSV) Nucleoside Analogs at the 8th Annual Respiratory Syncytial Virus Symposium
10/1/2012
-
Vertex Pharmaceuticals (MA) Vows to Fight on With Alios BioPharma Drugs in High-Stakes Hepatitis C Race
1/24/2012
-
Vertex Pharmaceuticals (MA) and Alios BioPharma Begin Clinical Studies of Nucleotide Drug Candidates ALS-2200 and ALS-2158 for the Treatment of Hepatitis C
12/9/2011
-
U.S. Biotech Alios BioPharma and Versitech Ltd. Announce Exclusive Worldwide Licensing Agreement for Influenza Technology
10/31/2011
-
Alios BioPharma Signs Flu Treatment Deal with University of Hong Kong
10/31/2011
-
Vertex Pharmaceuticals (MA) in Licensing Pact Potentially Worth $1.5 Billion With Alios BioPharma to Expand Hepatitis Pipeline
6/13/2011
-
Alios BioPharma Names Carol L. Brosgart, M.D., as Chief Medical Officer
2/7/2011